New: INUSpheresis® (known as Environmental Apheresis®)

The INUSpheresis® also known as Environmental Apheresis® is a new and innovative treatment at the Swiss Mountain Clinic, the international competence center for regulative and functional medicine. This form of treatment represents a special form of high-tech plasma purification and immune modulation for chronic and acute metabolic and immune system diseases (so-called autoimmune diseases) as well as for environmental medical stress.

How INUSpheresis® works

INUSpheresis® helps the body to rid itself of harmful proteins and metabolic products (e.g. cholesterol, etc.) or toxic substances (so-called paraproteins, tumour-associated proteins, circulating immune complexes, complex infectious toxins, pathoproteins, haptens) and to restore the deregulated metabolism/the inflammation cascade or the immune system to its natural balance (so-called metabolism/immunomodulation). INUSpheresis® does not produce a plasma exchange, does not lead to a significant loss of electrolytes or immune bodies, but is a gentle procedure which is very well tolerated and hardly burdens the organism.

It is used at the Swiss Mountain Clinic for environmental pollution, rheumatic diseases, lipid disorders, chronic diseases. Inflammations, condition after infectious diseases (e.g. Lyme disease) and autoimmune diseases.

Swiss Mountain Clinic

As of July the 6th, 2020, the Swiss Mountain Clinic is one of 10 registered Inuspherese® Centers in Europe and the only one in Switzerland. We follow the guidelines and recommendations of other international apheresis societies when determining indications and answering questions regarding apheresis therapy.

Advantages of Inuspheresis® treatment

Elimination of pathogenic components
Elimination of pathogenic components
Replacement for some burdenful medicines
Replacement for some burdenful medicines
Backflow of vital proteins
Backflow of vital proteins

Indications for INUSpheresis® at the Swiss Mountain Clinic

(in alphabetical order)
  • Age-related macular degeneration - dry course
  • Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Ulcerative colitis - failure of chemotherapy and/or threat of surgical removal of the bowel
  • Diabetic foot syndrome with threatened amputation of limbs in the event of failure of conservative and conventional surgical therapy
  • Dilated cardiomyopathy - beta-receptor antibody positive detection
  • Eaton-Lambert syndrome (tumor-associated nerve disorder)
  • Encephalitis disseminata (multiple sclerosis) - failure of interleukin-alpha therapy or antibody formation against therapeutic interleukin with progressive course
  • Familial heterocygous hypercholesterolemia with failure/NW of conservative therapy and/or premature and progressive atherosclerosis/heart attack/stroke/attack on renal vessels
  • Familial homocygous hypercholesterolemia
  • Focal sclerosing glomerulonephritis of the autologous kidneys or after kidney transplantation with nephrotic syndrome and/or severe hypertriglyceridemia with failure of chemotherapy/cholesterol synthesis inhibitor therapy and rapid increase in renal insufficiency (loss of kidney function)
  • Glomerulonephritis (inflammatory kidney disease) pathogenetically directed - failure and/or severe side effects of chemotherapy
  • Guillain Barre Syndrome - chronic/acute form
  • Haemophilia (hemophilia) with detection of antibodies against factor V
  • Inhibitor haemophilia (tendency to bleed) with factor V antibody detection
  • HLA sensitization in kidney transplantation
  • IgM associated polyneuropathy (tumour-associated nerve disorder)
  • Isolated familial Lp(a) hyperlipoproteinemia with premature atherosclerosis/heart attack/stroke/attack of renal vessels/operable arterial occlusive leg disease
  • Cryoglobulinemic vasculitis (autoimmune vasculitis caused by cold proteins)
  • Linear IgA dermatosis
  • Lupus erythematosus in failure/severe side effects of chemotherapy
  • Lupus erythematosus with progressive renal involvement (glomerulonephritis)
  • macular degeneration (adult form = adult) - dry form
  • Behcet's disease - failure and/or severe side effects of chemotherapy
  • Raynaud's disease - failure of conservative therapy
  • Refsum disease (memory disease)
  • Multiple sclerosis (see also Encephalitis disseminata)
  • Necrobiotic xanthogranulomatosis (with paraprotein)
  • Nephrotic syndrome in inflammatory kidney disease (glomerulonephritis) pathogenetically guided - failure and/or severe side effects of chemotherapy
  • Pemphigus foliaceus failure and/or severe side effects of chemotherapy
  • Pemphigus vulgaris failure and/or severe side effects of chemotherapy
  • Peripheral arterial occlusive disease (pathogenetically directed) in the event of failure of conservative and conventional surgical therapy options and threatened loss of limbs
  • Polymyositis - failure and/or severe side effects of chemotherapy
  • Retinopathy pigmentosa in Refsum disease
  • Rheumatoid arthritis - in failure of chemotherapy and extreme progression
  • Scleroderma progressive systemic with renal involvement (glomerulonephritis)
  • Scleromyxedema Arndt-Gottron - with kidney infestation and detection of paraprotein - failure and/or severe side effects of chemotherapy
  • Stiff-Man syndrome
  • Thrombangiitis obliterans (alternative to amputation)
  • Transplant vasculopathy after heart transplant
  • Xanthogranulomatosis (necrobiotic) with paraprotein

The INUSpheresis® is a highly effective substitute for some serious drugs. The choice of procedures and their dosage are adapted to the patient and his underlying problem.

Definition of INUSpheresis®

INUSpheresis® also known as Environmental Apheresis® is a treatment method whose therapeutic effects are based on the following action: The extracorporeal (outside of the body) elimination (removal) of pathogenic (disease-causing) proteins (proteins) and pathogenic substances bound to them. Pathogenic blood cells are also separated. Also environmental noxae, solvents and other toxic substances are separated.

With the help of double membrane filtration the pathogenic protein is removed from the separated plasma, which is then reinfused without significant loss of volume. A substitution solution is not required.

Simplified representation: Pathogenic components are removed from the body by a special type of blood purification. The disease-causing substances are filtered out - the purified plasma is returned to the body with all the good components.

outpatient and inpatient treatment possible
outpatient and inpatient treatment possible
Duration 2.5-3 hours
Duration 2.5-3 hours
Recommended treatment repetition after 3 days
Recommended treatment repetition after 3 days

The duration of an Inuspheresis® treatment is about 2.5 to 3 hours. The treatment can be carried out as an inpatient or outpatient. After an initial treatment we recommend a repetition after at least 2-3 days.

Additional Information

Innovative indications for INUSpheresis® as complementary treatment

These indications are to be understood as attempts to cure and treat (in the sense of the ultima ratio). These indications are listed alphabetically below:
  • Alzheimer dementia syndrome (pathogenesis see below)
  • Aerotoxic syndrome (pathogenesis see below)
  • Exposure to heavy metals, solvents and other environmental toxins that lead to serious autoimmune diseases and/or nervous diseases and/or skin diseases (e.g. aerotoxic syndrome, fibromyalgia, blistering skin diseases, toxic nerve damage, kidney damage, MCS, CFS, ciguatera poisoning, Parkinson's and dementia syndromes)
  • Lyme disease as late borreliosis with severe disease progressions that are no longer controllable conservatively (CFS/ Guillain-Barre Syndrome refractory to immunoglobulin therapy/ severe therapy-refractory autoimmune diseases, such as rheumatism, systemic collagenoses, lupus diseases, cardiomyopathies based on proven autoantibodies against the heart in Lyme disease)
  • Chronic Fatigue Syndrome (CFS)
  • Chronic Hepatitis C (in Japan health insurance benefit)
  • Fibromyalgia syndrome
  • Hypertension (high blood pressure) arterial- alpha1 and/or angiotensin 1 antibody positive detection- no or difficult treatment with conventional pharmacotherapy
  • Hyperbilirubinemia in severe congenital metabolic diseases of the liver with imminent brain damage
  • Multiple Chemical Hypersensitivity Syndrome (MCS)
  • Multiple Sclerosis (according to the study situation of the Canadian American Apheresis Society)

Difference in comparison to plasma - exchange

With the known plasma exchange, the entire separated (segregated) patient plasma is discarded, whereby not only pathogenic (disease-causing) proteins are eliminated, but also all other proteins that are essential for life. Therefore a substitution (replacement) with electrolytes (mineral salts), human albumin (human protein) or fresh plasma is necessary. This procedure sometimes shows side effects and strong reactions.

INUSpherese® is particularly suitable in environmental medicine

...as a closed blood/plasma cycle biophysical drainage procedure based on the laws of thermodynamics. INUS was the first institution to use this method specifically for chronic diseases. It was the first institution to use this method specifically for chronic diseases in environmental medicine and as a prevention. For this purpose, a proprietary procedure and device was developed. The INUS 300 is specifically adapted, the INUSpherese® is called Environmental Apheresis® and its effectiveness has been proven by us several times in a study with over 1000 patients.

This is used for removal:

  • Foreign substances that have reacted with proteins. (Haptene - artificially modified own proteins with a pathological and damaging character)
  • Secondary patho-proteins and pro-inflammatory (pro-inflammatory) proteins
  • Toxic (poisonous) substances such as heavy metals, solvents and environmental noxae
  • Rheological (changing the flow properties of the blood) proteins from the tissues

From 6th of July available at the Swiss Mountain Clinic